Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 3, 2026
Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?
View original at finance.yahoo.comIs Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline? Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Novo Nordisk DCF analysis suggests the stock is undervalued by 65.2% with an intrinsic value of US$106.21 per share compared to recent share price of US$36.98
60% confidenceNovo Nordisk scores 5 out of 6 on Simply Wall St's valuation checks
60% confidenceThe DCF model shows the stock trades at a 65.2% discount to intrinsic estimate, indicating valuation materially below the model's fair value output
60% confidence
Data points we hold from this source
| Novo Nordisk A/S · free cash flow | 52100000000.0 DKK |
| Novo Nordisk A/S · year to date return | -29.4 percent |
| Novo Nordisk A/S · 30 day return | 0.9 percent |
| Novo Nordisk A/S · valuation score | 5 out_of_6 |
| Novo Nordisk A/S · 7 day return | 1.6 percent |
| Novo Nordisk A/S · projected free cash flow 2030 | 111.09 billion_DKK |
| Novo Nordisk A/S · discount to intrinsic value | 65.2 percent |
| Novo Nordisk A/S · 1 year return | -43.1 percent |
| Novo Nordisk A/S · intrinsic value dcf | 106.21 USD |